Formula I Compounds Targeting HCV NS5B Polymerase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection are limited by the lack of effective vaccines and therapies, particularly for genotype 1, which have poor response rates and severe side effects, necessitating the development of more potent and safer antiviral drugs.
Innovation Solution
Development of novel compounds of formula I, which are effective against HCV, including pharmaceutically acceptable salts, that target specific mechanisms of action, such as binding, inhibition efficacy, target selectivity, solubility, and safety profiles, to treat HCV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard treatments (pegylated alpha-interferon and ribavirin) are used, then treatment coverage is provided, but treatment response rate is poor (only 50% for genotype 1) and side effects are severe
Solution Approach 1:
The patent employs parameter changes by developing novel chemical compounds with modified molecular structures (formula I with various substituents R1-R6) to achieve improved antiviral efficacy against HCV while reducing toxicity. The structural modifications allow optimization of pharmacological properties including potency, selectivity, and safety profile compared to existing therapies
Solution Approach 2:
The patent uses intermediary compounds that target specific HCV proteins (NS5B polymerase, NS3 protease) as mediators to inhibit viral replication. These compounds act as intermediate agents between the host immune system and the virus, providing targeted antiviral activity with fewer side effects than non-specific immunomodulators like interferon
2Reliability
If combination therapy with multiple drugs is used, then antiviral efficacy is enhanced, but treatment complexity and side effect profile increase
Solution Approach 1:
The patent merges multiple therapeutic functions into single molecular entities by designing compounds that can simultaneously target different HCV proteins or combine antiviral activity with anti-inflammatory properties. This consolidation reduces treatment complexity while maintaining or enhancing efficacy
Solution Approach 2:
The novel compounds exhibit multi-functionality by being capable of inhibiting multiple HCV proteases and polymerases across different genotypes, as well as potentially modulating host immune responses. This universal activity simplifies treatment regimens compared to genotype-specific therapies
3Reliability
If high doses of antiviral drugs are administered, then viral inhibition is improved, but toxicity and side effects increase
Solution Approach 1:
The patent applies local quality by designing compounds with selective targeting of HCV proteins through specific molecular interactions, concentrating antiviral activity at the viral replication sites while minimizing exposure and toxicity to healthy host tissues. The structural features (specific substituents and functional groups) enable selective binding to viral enzymes
4Reliability
If new antiviral compounds are developed, then treatment efficacy is improved, but development time and cost increase
Solution Approach 1:
The patent employs preliminary action through the use of subgenomic replicon systems and pseudotyped virus assays that allow early screening and evaluation of candidate compounds during development. These preliminary models enable rapid assessment of antiviral activity and mechanism of action before full-scale clinical development, reducing overall development time
Data Source
AI summary
The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.